Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche's new lung-cancer drug divarasib shows superior survival rates compared to rivals in late-stage trials, targeting the emerging oncology market.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Roche's KRAS drug divarasib beat rivals from Amgen and Bristol Myers Squibb in a pivotal late-stage lung cancer trial. The study showed the drug cut the risk of death by 44% and extended survival by nearly six months.
Roche described the phase 3 data as convincing.
Epilogue added 20d ago, after coverage quieted.
The brief
Roche has announced significant results from a phase 3 trial for its new lung-cancer medication, divarasib. According to reporting from Reuters, the drug demonstrated a 44% reduction in the risk of death for patients involved in the study. Data presented at the European Society for Medical Oncology (ESMO) conference indicates that the drug targets the KRAS mutation, with Roche describing the phase 3 data as convincing. These clinical results suggest a substantial improvement in patient outcomes within the oncology sector, specifically focusing on lung cancer treatments. Multiple major financial and industry outlets are tracking the development, including Bloomberg, the Wall Street Journal, Seeking Alpha, and Fierce Biotech.
Bloomberg reports that the drug has outshone rivals from Amgen and Bristol, while Seeking Alpha notes that the medication extended patient survival by nearly six months in the late-stage trial. The Wall Street Journal emphasizes that Roche is utilizing this drug to specifically target the emerging oncology market. The collective coverage highlights a competitive victory for Roche over other pharmaceutical entities currently operating in the same therapeutic space. This development is significant because it places Roche in a leading position against established competitors like Amgen and Bristol. The focus on KRAS data is a critical component of the current oncology landscape, as the ability to cut death risks by nearly half represents a major clinical milestone.
The timing of the announcement, coinciding with the ESMO event, underscores the importance of these findings to the broader medical community and the strategic importance of the lung-cancer market for Roche's business growth and market share. Observers will now look toward the next steps in the regulatory process for divarasib following the phase 3 win. Based on the coverage, the primary focus remains on how Roche will leverage this survival data to penetrate the emerging oncology market. Further attention will be directed toward whether the outcomes seen in the trial translate to widespread clinical adoption and how the rivals mentioned, namely Amgen and Bristol, respond to these results. The company's ability to maintain this competitive edge in the KRAS-targeted treatment sector will be a key point of interest.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 23d ago.
Quick answers
What is the name of the drug Roche is developing?
The drug is called divarasib.
How much did divarasib reduce the risk of death in the trial?
According to Reuters, the drug cut the risk of death by 44%.
Which competitors did the Roche drug outperform?
Bloomberg reports that the drug outshone rivals from Amgen and Bristol.
Coverage (9)
- Roche gets a lung cancer win with its KRAS drug divarasib STAT · 23d ago
- ESMO26: Roche's KRAS G12C inhibitor divarasib lives up to expectations in lung cancer study FirstWord Pharma · 23d ago
- Roche's experimental lung cancer drug beat two rivals in a pivotal trial Quartz · 23d ago
- Roche lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS) Seeking Alpha · 23d ago
- Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study Bloomberg.com · 23d ago
- ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals Fierce Biotech · 23d ago
- Roche says divarasib cut risk of death 44% in lung cancer trial Reuters · 23d ago
- Roche Targets Emerging Oncology Market With New Lung-Cancer Drug WSJ · 23d ago
- Roche takes victory lap with lung cancer pill's win over Amgen, BMS Endpoints News · 23d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Lung scans save lives: Denver man's early screening underscores dire need for more testing
A Denver man's life-saving lung scan during Lung Cancer Awareness Month spotlights urgent calls for expanded early screening nationwide.
As Hormone Use Increases, Some Doctors Warn Slight Cancer Risk Is Being Overlooked
Doctors warn of slight cancer risk with hormone therapy for menopause
Drinking 2-3 Cups of Coffee Daily Linked to 43% Lower Risk of Liver Cancer
Multiple studies link 2-3 cups of coffee daily to a 43% lower risk of liver cancer, with benefits seen for both caffeinated and decaf coffee.
Why is colorectal cancer aggressive in younger patients? Boston researchers discover new clues
Boston researchers uncover new clues explaining why colorectal cancer behaves so aggressively in younger patients.